ipamorelin growth hormone releasing peptide mechanism of action cjc-1295 secretagogue is one the several non-FDA approved Ipamorelin: The Ultimate Growth Hormone-Releasing

Absolute contraindications include: Active malignancy of any kind (GH and IGF-1 are growth-promoting signals) Active diabetic retinopathy (IGF-1 may worsen retinal vascularity) Pregnancy or breastfeeding Known hypersensitivity to any component of the formulation Pituitary tumours or untreated hypothalamic disease Relative contraindications requiring careful evaluation include pre-existing insulin resistance, type 2 diabetes, uncontrolled cardiovascular disease, and sleep apnoea (GH elevation can worsen upper airway tone in susceptible individuals)

M.ZahmatkeshM.XuJ.SoleimaniM.et al (2010)

Instead, the authors showed that hyperosmotic shock leads to breakdown of sphingomyelin, accumulation of ceramide, and later on to PS exposure and cell shrinkage

High EE% was obtained (73.30 0.74%) with DL% of 10.11 0.10%